Pharmacokinetics and Pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease

Clinical Therapeutics

Volumn 29, Issue 7, 2007, Pages 1368-1380

  Smith, William B ^a   Dowell, James A ^b   Pratt, Raymond D ^b  

^a New Orleans Center for Clinical Research   (United States)

^b SHIRE   (United States)

Author keywords

anemia; chronic kidney disease; epoetin delta; erythropoietin; pharmacokinetics; safety and tolerability

Indexed keywords

ERYTHROPOIETIN ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DYSPEPSIA; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FACE EDEMA; FEMALE; GANGRENE; GENERALIZED EDEMA; HEADACHE; HEMODIALYSIS; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; HYPOTENSION; LIMB PAIN; LUNG DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCLE CRAMP; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEPSIS; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; THROMBOSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRAL GASTROENTERITIS; VOMITING;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 34548355197     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.07.014     Document Type: Article

References (28)

1. Cella D. The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park) 16 Suppl 10 (2002) 125-132
2. Santoro A. Erythropoietin therapy and the cardiovascular system. Contrib Nephrol. 137 (2002) 431-435
3. Santoro A., and Canova C. Anemia and erythropoietin treatment in chronic kidney diseases. Minerva Urol Nefrol. 57 (2005) 23-31
4. Eckardt K. Managing a fateful alliance: Anaemia and cardiovascular outcomes. Nephrol Dial Transplant. 20 Suppl 6 (2005) vi16-vi20
5. Knight K., Wade S., and Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med. 116 Suppl 7A (2004) 11S-26S
6. Robinson B., Joffe M., and Berns J. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time [published correction appears in Kidney Int. 2005;68:2934]. Kidney Int. 68 (2005) 2323-2330
7. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant. 18 Suppl 2 (2003) ii7-ii12
8. Macdougall I. Quality of life and anemia: The nephrology experience. Semin Oncol. 25 Suppl 7 (1998) 39-42
9. Egrie J., and Browne J. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 16 Suppl 3 (2001) 3-13
10. Storring P., Tiplady R., and Gaines Das R. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 100 (1998) 79-89
11. Skibeli V., Nissen-Lie G., and Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98 (2001) 3626-3634
12. Varki A. Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. Am J Phys Anthropol. Suppl 33 (2001) 54-69
13. Hokke C., Bergwerff A., and van Dedem G. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Left 275 (1990) 9-14
14. Zhu A., and Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation 9 (2002) 376-381
15. Tangvoranuntakul P., Gagneux P., and Diaz S. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 100 (2003) 12045-12050
16. Rutherford C., Schneider T., and Dempsey H. Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: The importance of iron availability in optimizing response. Am J Med. 96 (1994) 139-145
17. Engert A. Recombinant human erythropoietin in oncology: Current status and further developments. Ann Oncol. 16 (2005) 1584-1595
18. Macdougall I. Erythropoietin and renal failure. Curr Hematol ReD 2 (2003) 459-464
19. Macdougall I. Poor response to erythropoietin: Practical guidelines on investigation and management. Nephrol Dial Transplant. 10 (1995) 607-614
20. Evens A., Bennett C., and Luminari S. Epoetin-induced pure red-cell aplasia (PRCA): Preliminary results From the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol. 18 (2005) 481-489
21. Kruger A., Schroer W., Rohrs F., and Vescio G. PRCA in a patient treated with epoetin beta. Nephrol Dial Transplant. 18 (2003) 1033-1034
22. Procrit [prescribing information] (2005), Ortho Biotech Products LP, Raritan, NJ
23. NeoRecormon [summary of product characteristics] (1997), Roche Registration Ltd, Welwyn Garden City, UK
24. Aranesp [summary of product characteristics] (2001), Amgen Europe BV, Breda, The Netherlands
25. Grzeszczak W., Sulowicz W., Rutkowski B., and European Collaborative Group. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis with chronic renal anaemia. Nephrol Dial Transplant. 20 (2005) 936-944
26. Krzyzanski W., Jusko W., and Wacholtz M. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci. 26 (2005) 295-306
27. Cournoyer D., Toffelmire E., and Wells G. Canadian PRCA Focus Group. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk. J Am Soc Nephrol. 15 (2004) 2728-2734
28. Macdougall I. Antibody-mediated pure red cell aplasia (PRCA): Epidemiology, immunogenicity and risks. Nephrol Dial Transplant. 20 Suppl 4 (2005) iv9-iv15